| Gender Preference | None |
| Age Group | 18 - 65 years |
| Research Start Date | July 1, 2012 |
| Research End Date | August 1, 2013 |
| Principal Investigator | Steven Polyak, MD |
| Description | A Phase 11 Study to Evaluate the Efficacy and Safety of 12 weeks Treatment With Oral CNDO 210 Trichuris Suis Ova Suspension(TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients with Moderatley to Severly Active Crohn's Disease(TRUST 1)
The Objective of this Phase II study is to evaluate the efficacy and safety of 12 weeks of treatment with oral CNDO 201 Trichuris suis ova suspension (TSO) as compared to placebo, followed by a 12 week open-label treatment period in patients with moderately to severely active Crohn’s disease. |
| Contact Info | Dr. Steven Polyak 319-353-8574
steven-polyak @uiowa.edu |
| Keywords | span itemProp='description'>Crohn ; Phase 11+Inflammatory bowel disease ; undefined ; |